JOURNEY
SpecialtyJOURNEY is a specialty pharmaceutical company focused on Dermatology. Key products include QBREXZA.
JOURNEY at a Glance
- Strong track record with 100% execution quality across 10 trials
- Fast trial execution (9 months median completion)
JOURNEY's Key Drugs
JOURNEY's core commercial portfolio centers on AMZEEQ, EMROSI, ZILXI, spanning Dermatology — its most strategically important drugs approved in the last 15 years.
JOURNEY's Recent FDA Approvals
JOURNEY secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
JOURNEY's Therapeutic Areas
JOURNEY's approved drugs and pipeline span 1 therapeutic area, led by Dermatology, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
JOURNEY's Top Competitors
JOURNEY's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
JOURNEY Pipeline Snapshot
Active clinical trials for JOURNEY across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMZEEQ leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/5 completed
- • Speed: 9 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges